These results are in line with our in vitro experiments using CD34+ cells derived from CML patients, where Lys05 treatment decreases the number of LTC-ICs and increases the CFCs derived from progenitor cells. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.